ArticleAmerican journal of ophthalmology case reports2018
Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema.
Article in American journal of ophthalmology case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interferons in vitreoretinal diseases; a review on their clinical application, and mechanism of action.International ophthalmology · 2024Pooled it
- Interferon as a novel agent for management of macular edema: Where do we stand?Indian journal of ophthalmology · 2026Review
- Comment on: Efficacy and safety of posterior subtenon interferon alfa-2B injection in recurrent inflammatory macular edema.Indian journal of ophthalmology · 2026Article
- Commentary: Topical interferon: A novel approach to uveitic macula edema.Indian journal of ophthalmology · 2022Article
- Topical interferon therapy in uveitic macular edema.Indian journal of ophthalmology · 2022Article
- Ocular Drug Delivery: Advancements and Innovations.Pharmaceutics · 2022Review
- Intensive topical interferon therapy in uveitic macular edema.Indian journal of ophthalmology · 2022Article
- Improvement of pseudophakic cystoid macular edema with subconjunctival injections of interferon α2b:a case report.American journal of ophthalmology case reports · 2022Article
- Current Management Options in Irvine-Gass Syndrome: A Systemized Review.Journal of clinical medicine · 2021Review
- Topical interferon - A novel treatment for pseudophakic macular edema.Indian journal of ophthalmology · 2021Article
- Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema.American journal of ophthalmology case reports · 2020Article
- Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac.Journal of clinical medicine · 2020Article
- Choroidal changes after intravitreal injection of interferon alpha-2b.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- Perioperative Management of Uveitic Cataracts.Advances in ophthalmology and optometry · 2019Article
- Topical Interferon Alpha 2b in the Treatment of Refractory Diabetic Macular Edema.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the efficacy and safety of interferon alpha 2b in the treatment of pseudophakic cystoid macular edema resistant to conventional therapy. OBSERVATIONS: A 64-year-old patient presented with pseudophakic cystoid macular edema in her left eye, which developed two months after an uncomplicated cataract surgery and was resistant to multiple topical NSAIDs and multiple intravitreal bevacizumab injections over the course of nine months. She also developed side effects to oral acetazolamide and intravitreal triamcinolone injection; a skin rash and a rise in intraocular pressure (34 mmHg), respectively. She was subsequently started on topical interferon alpha 2b (1 MIU/ml) four times a day nine months after developing pseudophakic cystoid macular edema. Cystoid macular edema improved significantly in four weeks and completely resolved after twelve weeks. Her vision improved from 20/100 before starting treatment to 20/25 twelve weeks after starting treatment. Macular structure and visual acuity were stable throughout a thirty-six weeks follow-up period.
conclusionsand Importance: This case report displays the potential efficacy and safety of interferon alpha 2b in the treatment of refractory cystoid macular edema after cataract surgery. Ocular surface irritation was the only reported adverse effect of the treatment in our patient, this responded to lubricants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.